Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease

2015 ◽  
Vol 35 (3) ◽  
pp. 333-336 ◽  
Author(s):  
Chao-lin Li ◽  
Lu-jie Zhao ◽  
Xin-li Zhou ◽  
Hui-xiao Wu ◽  
Jia-jun Zhao
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Dipeptidyl Peptidase ◽  
Alcoholic Fatty Liver ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Alcoholic Fatty Liver Disease

scholarly journals Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD)

2017 ◽  
Vol 5 (2) ◽  
pp. 54-59
Author(s):  
Ebrahim Abbasi Oshaghi
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Receptor Agonist ◽  
Alcoholic Fatty Liver ◽  
Dipeptidyl Peptidase 4 ◽  
New Finding ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence is estimated to be 24%. At present no approved medicines are available for NAFLD treatment. Glucagon-like peptide-1 (GLP-1) is a significant regulator of energy balance, show potential efficacy in the management of NAFLD. GLP-1 and GLP-1 receptor agonist (GLP-1RAs) are attractive options for the treatment of type 2 diabetes (T2D) since they efficiently reduce weight, HbA1C and blood glucose without having a risk of hypoglycaemia. This incretin hormone by normalizing of insulin resistance (IR), oxidative stress, lipid accumulation, lipotoxicity, and liver cell apoptosis is proposed for the management of NAFLD and nonalcoholic steatohepatitis (NASH) patient. Hence, the aim of this review was to discuss the useful effects of GLP-1, GLP-1 receptor agonist (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) on NAFLD. In this paper we provided a new finding which highlighted the role of GLP-1 and GLP-1RAs in the treatment of NAFLD.

scholarly journals Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e87488 ◽  
Author(s):  
Christine Bernsmeier ◽  
Anne C. Meyer-Gerspach ◽  
Lea S. Blaser ◽  
Lia Jeker ◽  
Robert E. Steinert ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Alcoholic Fatty Liver Disease

Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease

2016 ◽  
Vol 64 (4) ◽  
pp. 908-915 ◽  
Author(s):  
Anders E. Junker ◽  
Lise L. Gluud ◽  
Gerrit van Hall ◽  
Jens J. Holst ◽  
Filip K. Knop ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Glucagon Secretion ◽  
Alcoholic Fatty Liver ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document